Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.

Weisong LiChao ZhengXi XuYujie XiaKai ZhangAo HuangXinyu ZhangYong ZhengGuofang ChenShuyong Zhang

Published in: Cellular & molecular biology letters (2024)

These findings establish a preclinical foundation for the combined use of an anti-HER2 drug conjugate and a BRAF inhibitor in the treatment of BRAF-mutant cutaneous melanoma.

Keyphrases

wild type
metastatic colorectal cancer
cancer therapy
skin cancer
cell therapy
emergency department
stem cells
basal cell carcinoma
drug delivery
adverse drug
drug induced